LATUDA 40 MG — DIN 02387751
LURASIDONE HYDROCHLORIDE : 40 MG · SUMITOMO PHARMA CANADA, INC. · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LATUDA?
LATUDA 40 MG contains LURASIDONE HYDROCHLORIDE : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02387751, held by SUMITOMO PHARMA CANADA, INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Jun-2026. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is LATUDA used for?
Management of schizophrenia in adults and adolescents (15-17 years); monotherapy or adjunctive therapy for depressive episodes associated with bipolar I disorder (adults and adolescents 13-17).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Lurasidone cost around the world?
Lurasidone is listed on 7 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Iceland publishes a max wholesale. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 5 | 86 | USD███.██ |
| Greece | producer price (ex-factory) | 18 | 18 | EUR███.██ |
| Saudi Arabia | public | 7 | 17 | SAR███.██ |
| Australia | ex-manufacturer | 7 | 14 | AUD███.██ |
| Italy | prezzo al pubblico (classe A) | 6 | 12 | EUR███.██ |
| South Africa | single exit price | 5 | 5 | ZAR███.██ |
| Iceland | max wholesale | 1 | 3 | ISK███.██ |
155 pack listings across 49 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Lurasidone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Lurasidone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
8 holders have a Canadian DIN containing Lurasidone, across 40 DINs, of which 33 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| AURO PHARMA INC | 5 | 5 | AURO-LURASIDONE | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 5 | 5 | JAMP LURASIDONE | Sourceable in Canada |
| PHARMASCIENCE INC | 5 | 5 | PMS-LURASIDONE | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 5 | 5 | SANDOZ LURASIDONE | Sourceable in Canada |
| TARO PHARMACEUTICALS INC | 5 | 5 | TARO-LURASIDONE | Sourceable in Canada |
| NORA PHARMA INC | 5 | 4 | NRA-LURASIDONE | Sourceable in Canada |
| SANIS HEALTH INC | 5 | 4 | LURASIDONE | Sourceable in Canada |
| SUMITOMO PHARMA CANADA, INC. | 5 | 0 | LATUDA | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 40 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg film-coated tablets. (Specific container types not listed in provided text). |
| Storage | Not specified in the provided text snippet (section exists in full monograph but details are cut off). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lurasidone |
|---|---|
| ATC code | N05AE05 |
| AHFS class | 28:16.08.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02387751 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2387751 |
| Brand name | LATUDA |
| Generic / active ingredient | LURASIDONE HYDROCHLORIDE : 40 MG |
| Market authorization holder | SUMITOMO PHARMA CANADA, INC. |
| Health Canada schedule | Prescription |
| ATC code | N05AE05 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05AE |
| Current status | CANCELLED POST MARKET |
| Status date | 30-Jun-2026 |
| Original market date | 2012-09-06 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Administer orally with food (at least 350 calories). Available in 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg tablets. Dosage varies by indication and age group.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to lurasidone HCl; concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin).
Warnings and precautions
Increased mortality in elderly patients with dementia. Risk of Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, orthostatic hypotension, and metabolic changes.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
33 of 40 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-LURASIDONE | 40 MG | TABLET | AURO PHARMA INC | MARKETED | 02513994 |
| AURO-LURASIDONE | 60 MG | TABLET | AURO PHARMA INC | MARKETED | 02514001 |
| AURO-LURASIDONE | 20 MG | TABLET | AURO PHARMA INC | MARKETED | 02513986 |
| AURO-LURASIDONE | 120 MG | TABLET | AURO PHARMA INC | MARKETED | 02514036 |
| AURO-LURASIDONE | 80 MG | TABLET | AURO PHARMA INC | MARKETED | 02514028 |
| JAMP LURASIDONE | 80 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02516462 |
| JAMP LURASIDONE | 40 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02516446 |
| JAMP LURASIDONE | 20 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02516438 |
| JAMP LURASIDONE | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02516454 |
| JAMP LURASIDONE | 120 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02516470 |
2 · Same class — other molecules in ATC N05AE
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lurasidone | AURO-LURASIDONE · JAMP LURASIDONE · LATUDA · LURASIDONE · +4 more | 40 | 33 | Yes |
| Ziprasidone | AURO-ZIPRASIDONE · GD-ZIPRASIDONE · MYLAN-ZIPRASIDONE · PMS-ZIPRASIDONE · +1 more | 20 | 8 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N05A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N05AH | Asenapine · Clozapine · Loxapine · Olanzapine · Quetiapine | 589 | 220 |
| N05AX | Aripiprazole · Brexpiprazole · Cariprazine · Paliperidone · Risperidone | 352 | 175 |
| N05AB | Fluphenazine · Perphenazine · Prochlorperazine · Thioproperazine · Trifluoperazine | 104 | 10 |
| N05AD | Droperidol · Haloperidol | 53 | 9 |
| N05AF | Flupentixol · Tiotixene · Zuclopenthixol | 25 | 8 |
| N05AA | Chlorpromazine · Levomepromazine · Promazine | 51 | 8 |
| N05AN | Lithium | 26 | 7 |
| N05AC | Mesoridazine · Periciazine · Pipotiazine · Thioridazine | 32 | 3 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is LATUDA called?
Also recorded in Canada as: lurasidone hydrochloride 40 MG Oral Tablet [Latuda] (US), lurasidone hydrochloride 80 MG Oral Tablet [Latuda] (US), lurasidone hydrochloride 20 MG Oral Tablet [Latuda] (US), lurasidone hydrochloride 120 MG Oral Tablet [Latuda] (US), lurasidone hydrochloride 60 MG Oral Tablet [Latuda] (US), lurasidone hydrochloride 40 MG Oral Tablet (US), lurasidone hydrochloride 80 MG Oral Tablet (US), lurasidone hydrochloride 20 MG Oral Tablet (US), lurasidone hydrochloride 120 MG Oral Tablet (US), lurasidone hydrochloride 60 MG Oral Tablet (US), LURASIDONE HYDROCHLORIDE (US).
The same molecule, Lurasidone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Elbaluran | Latin | Saudi Arabia |
| Laroza | Latin | Saudi Arabia |
| Debilur | Latin | Saudi Arabia |
| APO-Lurasidone | Latin | Australia |
| Lavione | Latin | Australia |
| Lurasidone Lupin | Latin | Australia |
| Lurasidone Sandoz | Latin | Australia |
| LURASIDONE SUN | Latin | Australia |
| LURASIDONE-WGR | Latin | Australia |
| Novus | Latin | Saudi Arabia |
| Pharmacor Lurasidone | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.